PALATIN TECHNOLOGIES, INC. Operating Lease, Right-of-Use Asset, Amortization Expense
PALATIN TECHNOLOGIES, INC. (PTN) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $126.44 thousand for the 9-month period ending 2026-03-31, per its 10-Q filed 2026-05-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2026-05-13
- PALATIN TECHNOLOGIES, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-03-31 was $63.32K, a 31.01% decline year-over-year.
- PALATIN TECHNOLOGIES, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-12-31 was $31.78K, a 64.88% decline year-over-year.
- PALATIN TECHNOLOGIES, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-09-30 was $31.34K, a 64.86% decline year-over-year.
- PALATIN TECHNOLOGIES, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-06-30 was $94.70K, a 7.67% increase year-over-year.
- PALATIN TECHNOLOGIES, INC. operating lease, right-of-use asset, amortization expense for fiscal 2025 was $366.15K, a 4.98% increase from fiscal 2024.
- PALATIN TECHNOLOGIES, INC. operating lease, right-of-use asset, amortization expense for fiscal 2024 was $348.78K, a 6.08% decline from fiscal 2023.
- PALATIN TECHNOLOGIES, INC. operating lease, right-of-use asset, amortization expense for fiscal 2023 was $371.34K.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 3 month | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month | Operating Lease, Right-of-Use Asset, Amortization Expense 9 month | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month |
|---|---|---|---|---|
| 2026-03-31 | $63.32K derived: 10-Q 9 month − 10-Q 6 month · filed 2026-05-13 | $95.10K derived: sum of 2 quarters · filed 2026-05-13 | $126.44K 10-Q · filed 2026-05-13 | $221.13K derived: sum of 4 quarters · filed 2026-05-13 |
| 2025-12-31 | $31.78K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-02-17 | $63.12K 10-Q · filed 2026-02-17 | $157.82K derived: sum of 3 quarters · filed 2026-02-17 | $249.60K derived: sum of 4 quarters · filed 2026-05-13 |
| 2025-09-30 | $31.34K 10-Q · filed 2025-11-14 | $126.04K derived: sum of 2 quarters · filed 2025-11-14 | $217.82K derived: sum of 3 quarters · filed 2026-05-13 | $308.30K derived: sum of 4 quarters · filed 2026-05-13 |
| 2025-06-30 | $94.70K derived: 10-K 12 month − 10-Q 9 month · filed 2025-09-23 | $186.48K derived: sum of 2 quarters · filed 2026-05-13 | $276.96K derived: sum of 3 quarters · filed 2026-05-13 | $366.15K 10-K · filed 2025-09-23 |
| 2025-03-31 | $91.78K derived: 10-Q 9 month − 10-Q 6 month · filed 2026-05-13 | $182.26K derived: sum of 2 quarters · filed 2026-05-13 | $271.46K 10-Q · filed 2026-05-13 | $359.41K derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $90.48K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-02-17 | $179.68K 10-Q · filed 2026-02-17 | $267.63K derived: sum of 3 quarters · filed 2026-02-17 | $354.36K derived: sum of 4 quarters · filed 2026-02-17 |
| 2024-09-30 | $89.20K 10-Q · filed 2025-11-14 | $177.15K derived: sum of 2 quarters · filed 2025-11-14 | $263.88K derived: sum of 3 quarters · filed 2025-11-14 | $349.42K derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | $87.95K derived: 10-K 12 month − 10-Q 9 month · filed 2025-09-23 | $174.68K derived: sum of 2 quarters · filed 2025-09-23 | $260.22K derived: sum of 3 quarters · filed 2025-09-23 | $348.78K 10-K · filed 2025-09-23 |
| 2024-03-31 | $86.73K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-05-14 | $172.27K derived: sum of 2 quarters · filed 2025-05-14 | $260.83K 10-Q · filed 2025-05-14 | $353.15K derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $85.53K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-02-13 | $174.10K 10-Q · filed 2025-02-13 | $266.41K derived: sum of 3 quarters · filed 2025-02-13 | $360.70K derived: sum of 4 quarters · filed 2025-02-13 |
| 2023-09-30 | $88.56K 10-Q · filed 2024-11-14 | $180.88K derived: sum of 2 quarters · filed 2024-11-14 | $275.17K derived: sum of 3 quarters · filed 2024-11-14 | $368.17K derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $92.32K derived: 10-K 12 month − 10-Q 9 month · filed 2024-09-30 | $186.60K derived: sum of 2 quarters · filed 2024-09-30 | $279.61K derived: sum of 3 quarters · filed 2024-09-30 | $371.34K 10-K · filed 2024-09-30 |
| 2023-03-31 | $94.29K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-05-15 | $187.29K derived: sum of 2 quarters · filed 2024-05-15 | $279.02K 10-Q · filed 2024-05-15 | |
| 2022-12-31 | $93.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-02-14 | $184.74K 10-Q · filed 2024-02-14 | ||
| 2022-09-30 | $91.73K 10-Q · filed 2023-11-14 | |||
| 2022-03-31 | $268.86K 10-Q · filed 2023-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B |